Secondary prevention for ischaemic heart disease can be defined as a comprehensive set of measures, aiming to reduce the recurrence of cardiovascular disease and to improve long-term prognosis. Despite its proven efficacy, uptake and adherence rates remain poor. This paper summarises the available European recommendations for secondary prevention in varying ischaemic heart disease populations, including those patients with specific co-morbidities. The scientific evidence supporting these recommendations is provided.
The umbrella of preventive cardiology encompasses both primary and secondary prevention of cardiovascular disease, the latter of which will be the focus of this article. Secondary prevention aims to stop and/or slow down the progress of established cardiovascular disease, to improve functional capacity, to restore quality of life and to reduce the risk of disease recurrence. 1 It is strongly recommended to use a comprehensive approach comprising multiple core components: (a) patient assessment; (b) physical activity counselling and exercise training prescription; (c) nutritional counselling; (d) risk factor control; (e) psychosocial management; (f) vocational support; (g) therapy adherence; and (h) patient education. 2 Such a multidimensional approach assures an adequate delivery of information, which has turned out to be a particular challenge, in particular regarding not only the initiation of but also long-term adherence to lifetime changes. Many patients report not receiving robust encouragement from physicians and other health professionals with regard to the prevention of recurrent events. At the same time, self-monitoring of risk factors and action planning seems to be helpful. Therefore, all professionals involved in the cardiac patient's care with their detailed knowledge of an individual's social, medical and/or cultural background are called upon to help them find the most suitable form of a structured preventive cardiovascular programme.
Traditionally three main phases have been differentiated (the in-hospital phase I, the early out-patient phase II and the long-term maintenance phase III). However, in essence, secondary prevention is an uninterrupted, patient-tailored and lifelong care strategy to encourage and enable cardiac patients to resume a normal life. Despite the standardisation of objectives and core components of cardiac rehabilitation programmes, the structure, content, duration, intensity and volume of programmes continues to differ widely between, and within, different European countries. Differences in local and national guidelines, legislation, as well as reimbursement factors are held responsible for this disparity.
Rationale
The most recent European Heart Network statistics indicate that cardiovascular disease accounts for 47% of all deaths in Europe, thereby currently constituting a disease category of the highest public relevance. 4 Each year seven million people suffer from an acute coronary syndrome. 5 Despite the current era of acute revascularisation and evidence-based pharmacotherapy (including angiotensin-converting-enzyme (ACE) inhibitors, anti-platelet therapy, b-blockers and statins), mortality rates one year after a myocardial infarction remain in the region of 10%. 6 About half of the patients that suffer from a major acute coronary event have a history of an acute myocardial infarction. 7 These statistics clearly indicate the need for large-scale deployment, referral to, uptake of and adherence to high-quality secondary prevention programmes in order to improve long-term outcomes. Unfortunately, as indicated by the European survey on the management of ischaemic heart disease in 24 European countries (EUROASPIRE IV), <50% of patients access/are referred to and adhere to these programmes due to patient-, healthcare provider-and health system-based barriers. 8, 9 As a consequence, the European Association of Preventive Cardiology (EAPC) in collaboration with the Acute Cardiovascular Care Association (ACCA) and the Council on Cardiovascular Nursing and Allied Professions (CCNAP) called for action. In their 'Secondary Prevention After Acute Myocardial Infarction' position statement, they outlined today's challenges and how to address these. 10 The purpose of this paper is to provide the reader with (a) the European Society of Cardiology (ESC) guidelines recommendations regarding secondary prevention for different ischaemic heart disease populations, and (b) the relevant clinical evidence supporting these recommendations.
Who will benefit from secondary prevention? Ischaemic heart disease patients
Patients who suffered from a ST-elevation acute myocardial infarction (STEMI) are at high-risk for recurrence and premature death. Therefore the ESC guidelines recommend the initiation of several secondary prevention related lifestyle interventions and pharmacological treatments during the hospital stay for the initial cardiac event.
11 Key lifestyle interventions include smoking cessation (Class I, Level B) and cardiovascular risk factor control. Nutritional counselling, stress management and early resumption of professional activities are encouraged. Participation in an outpatient and/or centre-based exercise-based cardiac rehabilitation programme is indicated in all patients (Class I, Level B).
Enrolment in a comprehensive secondary prevention programme should also be considered for patients who suffered from an acute coronary syndrome type non-ST-elevation myocardial infarction (NSTEMI) (Class IIa, Level A) to enhance patient compliance, to promote sustained healthy lifestyle behaviour change and to allow for nutritional/psychological and vocational counselling. 12 All patients should be recommended to stop smoking (Class I, Level A), to engage in regular physical activities (Class I, Level A) and to adopt a heart-friendly diet (Class I, Level A). Physical activities preferably include aerobic exercise training with a frequency of 3 times a week and a duration of 30 min per session.
Long-term, structured and multidisciplinary cardiac rehabilitation, aiming to reduce symptoms and to improve prognosis, is also recommended for patients with stable coronary artery disease (Class I, Level A). 13 It encompasses lifestyle modification, pharmacological treatment, cardiovascular risk factor modification and patient education as in patients after an acute coronary syndrome. Stable coronary artery disease patients are encouraged to engage in moderate-tovigorous intensity aerobic exercise training, 3 times a week and for 30 min per session, as part of the cardiac rehabilitation programme.
According to the ESC guidelines, comprehensive secondary prevention should thus be considered and/ or recommended for all types of ischaemic heart disease (both STEMI, NSTEMI and stable coronary artery disease patients) within this era of acute revascularisation and highly effective evidence-based pharmacotherapy. The scientific evidence supporting these recommendations has recently been summarised in two systematic reviews. 14, 15 The Cardiac Rehabilitation Outcome Study (CROS) 14 assessed the prognostic effect of multi-component cardiac rehabilitation in the modern era, i.e. after the introduction of acute percutaneous coronary intervention and the administration of statins in patients who suffered from an acute coronary syndrome, who received a coronary artery bypass graft or who suffered from stable coronary artery disease. It included 25 studies performed after 1995 (n ¼ 1 randomised controlled trial (RCT), n ¼ 7 prospective controlled cohort studies, n ¼ 17 retrospective controlled cohort studies; mean follow-up period: 40 months), evaluating 219,702 patients and reflecting routine clinical practice in nine countries worldwide. The major finding of CROS was that multi-component cardiac rehabilitation is still associated with a reduced total mortality when compared to usual care for acute coronary syndrome (hazard ratio (HR) 0.37, 95% confidence interval (CI) (0.20-0.69)) and coronary artery bypass graft patients (HR 0.62, 95% CI (0.54-0.70)) in the era of acute coronary revascularisation and modern medical treatment. The latest Cochrane review assessing the effectiveness of all available studies on exercise-based cardiac rehabilitation in ischaemic heart disease by pooling the results of 63 RCTs (14,486 patients; mean follow-up time of 12 months) concluded that exercise-based cardiac rehabilitation is effective in reducing cardiovascular mortality by 26% (relative risk: 0.74; 95% CI (0.64-0.86)). 15 These results confirm the additional benefits of cardiac rehabilitation within the context of contemporary medical treatments and justify a Class I recommendation of current clinical guidelines to attend cardiac rehabilitation for patients with ischaemic heart disease.
Ischaemic heart disease in specific patient populations
Elderly and frail patients. Frailty constitutes an important issue in cardiac rehabilitation programmes, since elderly patients (>75 years) represent up to one-third of the cardiac rehabilitation population, even though advanced age is frequently reported as an important barrier for participation in secondary prevention programmes. 16 According to the widely adopted Fried's phenotype frailty index, it is defined as a phenotypic presentation involving decline in physical functioning and psychological status, without taking into consideration associated diseases or pathological conditions. It is based on the five health domains: nutrition, physical exhaustion, low energy expenditure or inactivity status, mobility and muscular strength.
Frailty measurements during the initial assessment should be considered for optimisation of: (a) type and timing of diagnostic procedures, (b) pharmacological and nonpharmacological treatment and (c) exercise prescription.
Frailty complicates the management of elderly patients, because it affects the validity of diagnostic procedures and makes exercise prescription and starting of exercise training difficult. Therefore, a pragmatic approach is recommended, starting physical mobilisation with caution and focusing on improvement of balance, gait safety and posture maintenance.
Tailored exercise training has been shown in community living or institutionalised frail elderly patients to improve physical function and quality of life to some degree. 17, 18 Although it is still uncertain whether these positive results can be applied to cardiac rehabilitation patients, frail patients should be offered exercise-based rehabilitation programmes in order to improve physical mobility, functional capacity and quality of life; and to prevent falls and disability. Special importance in the elderly should also be attached at nutritional aspects, since poor nutritional status is one of the main pathophysiological mechanisms for frailty. Recent studies suggest that improving nutritional status may reduce the risk of frailty. 19 Diabetic patients. Impaired glucose tolerance is one of the strongest prognosticators after acute myocardial infarction and diabetes mellitus is associated with an increased risk of coronary artery disease and an impaired prognosis after the acute myocardial infarction. Nevertheless, a substantial proportion of adults meeting the criteria of diabetes are not identified as such. Therefore adequate diagnosis and treatment is of utmost importance. Controversies exist as to the extent to which glycaemic control should be undertaken in diabetic patients with an acute coronary syndrome, as the deleterious impact of hypoglycaemia on cardiovascular outcomes has been increasingly recognised. 20 According to the 2013 ESC/European Association for the Study of Diabetes Guidelines, glucose-lowering therapies should be considered in acute coronary syndrome patients with significant hyperglycaemia (glucose concentration >10 mmol/l (>180-200 mg/dl)) and moderately tight glycaemic control (6.6-9.9 mmol/l or 120-180 mg/dl) is independently associated with lower mortality and major complications than that observed after tighter (<6.6 mmol/l or <120 mg/dl) or more lenient (>9.9 mmol/l or >180 mg/dl) glycaemic control. 21 As a general rule, with more advanced cardiovascular disease, older age, longer diabetes duration and more co-morbidities, less stringent glucose control should be applied in the acute phase and at follow-up.
Physical activity is not only important in the prevention of the development of type 2 diabetes in people with impaired glucose tolerance but also for the control of glycaemia and related cardiovascular disease complications. 22 Aerobic and resistance training improve insulin action and plasma glucose, lipids, blood pressure and cardiovascular risk. 23 However, regular exercise is necessary for continuing benefit. Combined aerobic and resistance training has in the matter a more favourable impact on Hemoglobin A1c (HbA1c) than aerobic or resistance training alone and is able to reduce HbA1c by 0.7%, compared with controls. 24 Structured exercise of >150 min/week is associated with a fall in HbA1c of 0.9%, 150 min/week with a fall of 0.4%. It should be noted, however, interventions of physical activity advice are associated with lower HbA1c levels only when combined with dietary advice. 25 Chronic kidney disease patients. The prevalence of chronic kidney disease (estimated Glomerular Filtration Rate (eGFR) < 60 ml/min/1.73 m 2 ) in a big cohort of patients in a stationary rehabilitation setting was as high as 38.2%. 26 Depending on the duration and classification of renal failure, a moderate to severe reduction of physical capacity must be expected. This is related to renal anaemia, uraemic myopathy and polyneuropathy, disturbances in volume status, electrolyte balance and or acid-base metabolism as well as physical inactivity. For a given patient, exercise training should depend on the baseline level of physical capacity and kidney disease severity, however stage I-III renal failure should not affect the ability to perform exercise. In haemodialysis patients, special attention should be paid to avoid injury of the arteriovenous fistula and pain in the shuntarm. Exercise training should be performed on the day between haemodialysis sessions. In general, patients with coronary artery disease complicated with chronic kidney disease may gain benefit rather than to risk harm from participation in cardiac rehabilitation in terms of eGFR, exercise capacity and plasma Brain natriuretic peptide (BNP) concentration. 27 Left ventricular dysfunction/heart failure patients. Physical inactivity is common in patients with symptomatic heart failure and contributes to its progression. Exercise training improves exercise capacity and quality of life, it does not adversely affect left ventricular remodelling, and may reduce mortality and hospitalisation rate in patients with mild-to-moderate chronic heart failure. Hence, regular aerobic exercise is recommended to improve functional capacity and symptoms, in both heart failure patients with reduced or preserved ejection fraction (Class I, level A). 28, 29 Enrolment in a multidisciplinary care management programme reduces the risk of heart failure hospitalisation and mortality and is recommended (Class I, level A).
Female patients. Physicians often misunderstand cardiovascular disease risks in women, and this corresponds with poor referral to cardiac rehabilitation, although women benefit from comprehensive cardiac rehabilitation as much as men. 30 This is also true for older women. At recruitment to cardiac rehabilitation, women typically score lower in health-related quality of life and they are more likely to be diagnosed with depressive disorders and higher scores of anxiety. The planning and implementation of cardiac rehabilitation in women needs to consider that they are more likely to be older, to have hypertension, diabetes, hypercholesterolaemia, obesity and heart failure, as well as lower exercise and functional capacity compared to male patients and may therefore carry a higher cardiac risk. Beyond the impact of the cardiac disease, older women in particular are more likely to experience activity limitations and other exercise-limiting co-morbid conditions such as arthritis, osteoporosis and urinary incontinence. However, cardiac rehabilitation constitutes the standard of care also for women, and this standard should be upheld for all women with cardiovascular disease, regardless of age, race, socioeconomic status or co-morbidities. 31 
Conclusion
In the current ESC guidelines, comprehensive secondary prevention is recommended for patients with various types of ischaemic heart disease (STEMI, NSTEMI and stable coronary artery disease patients). The most recent scientific evidence (i.e. the CROS study and Cochrane review) demonstrates additional benefits of cardiac rehabilitation within the contemporary era of acute revascularisation and highly effective evidencebased pharmacotherapy and hence justifies a Class I recommendation. Healthcare professionals should be encouraged to assess relevant co-morbidities in all ischaemic heart disease patients in order to improve care delivery. Frailty screening is strongly recommended in elderly patients to optimise pharmacological treatment and to tailor exercise prescription. Timely identification and proper treatment of concomitant diabetes mellitus is paramount. The presence of chronic kidney disease and/or heart failure should not prevent patients from attending cardiac rehabilitation. Genderspecific exercise-limiting co-morbid conditions should be taken into account when prescribing training programmes for female patients.
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